Silence Therapeutics (NASDAQ:SLN - Get Free Report)'s stock had its "buy" rating reissued by analysts at Chardan Capital in a note issued to investors on Tuesday,Benzinga reports. They currently have a $55.00 target price on the stock.
Other equities research analysts also recently issued research reports about the company. HC Wainwright reissued a "buy" rating and set a $75.00 price target on shares of Silence Therapeutics in a research report on Monday. William Blair reissued an "outperform" rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. Morgan Stanley reissued an "overweight" rating and set a $49.00 price target on shares of Silence Therapeutics in a research report on Tuesday, October 8th. BMO Capital Markets reaffirmed an "outperform" rating on shares of Silence Therapeutics in a research report on Monday, December 2nd. Finally, Jefferies Financial Group began coverage on Silence Therapeutics in a research report on Tuesday, September 3rd. They issued a "buy" rating and a $40.00 target price for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $57.20.
View Our Latest Report on SLN
Silence Therapeutics Price Performance
SLN stock traded down $0.59 during trading on Tuesday, reaching $7.40. 580,906 shares of the stock traded hands, compared to its average volume of 263,485. The business's 50 day moving average price is $14.64 and its 200-day moving average price is $17.50. Silence Therapeutics has a 52-week low of $5.81 and a 52-week high of $27.72. The firm has a market capitalization of $221.47 million, a PE ratio of -5.09 and a beta of 1.05.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of SLN. Legato Capital Management LLC acquired a new position in shares of Silence Therapeutics in the second quarter worth about $376,000. Custom Index Systems LLC acquired a new position in shares of Silence Therapeutics in the second quarter worth about $282,000. Nicholas Investment Partners LP acquired a new position in shares of Silence Therapeutics in the second quarter worth about $2,859,000. First Turn Management LLC acquired a new stake in Silence Therapeutics during the second quarter valued at approximately $10,209,000. Finally, Lombard Odier Asset Management USA Corp raised its stake in Silence Therapeutics by 0.7% during the second quarter. Lombard Odier Asset Management USA Corp now owns 2,405,998 shares of the company's stock valued at $45,714,000 after buying an additional 17,086 shares in the last quarter. Institutional investors and hedge funds own 98.73% of the company's stock.
About Silence Therapeutics
(
Get Free Report)
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
Read More
Before you consider Silence Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Silence Therapeutics wasn't on the list.
While Silence Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
